Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Fighting Resistant Blood Cancer Cells

21.06.2016

Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches

Chronic myeloid leukemia (CML) develops through chromosomal alterations in blood-forming cells of the bone marrow and usually occurs in older persons. Around 20 percent of adults diagnosed with leukemia suffer from this type of blood cancer. The protein Gab2 works as an enhancer of cancer-causing signals and is often present in larger quantities in CML cells than in healthy cells.


Blood cell producing bone marrow cells. Image by: Konrad Aumann

In two studies, Freiburg researchers have made new discoveries concerning the relationship between CML and Gab2 and drugs that can break a particular resistance to Gab2 in CML cells. The team, including Dr. Tilman Brummer, Prof. Dr. Jörn Dengjel, Dr. Konrad Aumann, and Dr. Sebastian Halbach, published its findings in the journals Leukemia and Cell Communication and Signaling.

Dr. Gabriele Kröner, managing director of the José Carreras Leukemia Foundation, is delighted with the results: “Research means progress in the battle against diseases. Supporting innovative research projects like this is one of our main objectives at the nonprofit José Carreras Leukemia Foundation. The 200,000 euros in funding the José Carreras Leukemia Foundation contributed to the project was therefore a good use of donations.”

The protein Gab2 works like a multi-outlet power strip for proteins in a chain of signals: It can pass on a signal it receives to several enzymes at once and can also amplify the signal. When a large amount of Gab2 is present, it often develops cancer-causing properties. In CML cells, Gab2 amplifies the signal of the protein Bcr-Abl. This protein causes certain cells in the bone marrow and in the blood to grow uncontrollably, thus allowing the cancer to spread more rapidly.

An approach often used in treating CML is to block the Bcr-Abl activity using tyrosine kinase inhibitors (TKIs). Yet even when this targeted therapy is successful, it is not possible to kill off all of the diseased cells – particularly the leukemia stem cells in the bone marrow. Lifelong treatment is necessary to keep the disease under control.

Many leukemias acquire a resistance to the TKIs used for the therapy over time, and the patient suffers a relapse. To make matters worse, there are also forms of primary resistance in which the leukemia cells react insufficiently to certain TKIs from the outset. The primary and acquired resistances are a major stumbling block in the treatment of CML that is still only poorly understood.

The Freiburg team demonstrated that the drugs sorafenib and axitinib, which are currently approved only for kidney and liver cancer, are effective in CML model systems as well. In experiments on cell cultures, both of these inhibitors succeeded in breaking various forms of the TKI resistance: including forms caused by additional mutations of the gene Bcr-Abl as well as those caused by large quantities of the protein Gab2. Hence, both of the drugs could serve as alternatives for treating CML – especially in patients who have developed a resistance to the medication they have been receiving so far.

In addition, the researchers provided evidence that Gab2 plays an important part in the development and spread of CML. In a mouse model in which they simulated the development of CML by adding Bcr-Abl to the bone marrow, a shortage of Gab2 led to a clear weakening or even a lack of symptoms. This shows that Gab2 is crucial for the development and spread of the disease. In the future, doctors could thus use Gab2 as a biomarker and infer the course of the disease by measuring Gab2 levels. In addition, Gab2 could serve as a new therapeutic target in the treatment of CML.

Tilman Brummer heads a research group at the University of Freiburg’s Institute of Molecular Medicine and Cell Research. Sebastian Halbach conducts research in Brummer’s group and is a former member of the Spemann Graduate School of Biology and Medicine (SGBM). Jörn Dengjel was a group leader at the university’s Center for Systems Biology, but has since moved on to the University of Fribourg in Switzerland. Brummer is a member of the Freiburg Cluster of Excellence BIOSS Centre for Biological Signalling Studies and a principal investigator at the SGBM and at collaborative research center 850, “Control of Cell Motility in Morphogenesis, Cancer Invasion, and Metastasis,” also located at the University of Freiburg. The study published in Leukemia was conducted in close cooperation with Dr. Konrad Aumann from the Institute of Clinical Pathology at the Freiburg University Medical Center and with assistance from the lab of BIOSS member Prof. Dr. Robert Zeiser, Department of Medicine I, Freiburg University Medical Center.

Original publications:
S. Halbach, Z. Hu, C. Gretzmeier, J. Ellermann, F.U. Wöhrle, J. Dengjel, and T. Brummer (2016). Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. Cell Commun Signal 14(1): 6. DOI: 10.1186/s12964-016-0129-y

S. Halbach, M. Köhler, F. M. Uhl, J. Huber, R. Zeiser, S. Koschmieder, K. Aumann, and T. Brummer (2016). Gab2 is essential for Bcr-Abl mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model. Leukemia. DOI: 10.1038/leu.2016.92

Article on Tilman Brummer’s research in uni’wissen:
www.pr2.uni-freiburg.de/publikationen/uniwissen/uniwissen-2016-1/page1.html#/8

Contact:
Dr. Tilman Brummer
Institute of Molecular Medicine and Cell Research
University of Freiburg
Phone: +49 (0)761/203-9610
E-Mail: tilman.brummer@zbsa.uni-freiburg.de

Weitere Informationen:

https://www.pr.uni-freiburg.de/pm/2016/pm.2016-06-20.95-en?set_language=en

Rudolf-Werner Dreier | Albert-Ludwigs-Universität Freiburg im Breisgau

More articles from Life Sciences:

nachricht Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)

nachricht CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

New Study Will Help Find the Best Locations for Thermal Power Stations in Iceland

19.01.2017 | Earth Sciences

Not of Divided Mind

19.01.2017 | Life Sciences

Molecule flash mob

19.01.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>